CEA vs Carotid Artery Stenting: CREST Trial Evidence

June 2, 2026

The Two Procedures

Carotid Endarterectomy (CEA): Open surgical removal of the atherosclerotic plaque from the carotid bifurcation and proximal ICA under general or regional anesthesia. The original intervention proven to reduce stroke in the landmark NASCET (1991) and ECST (1998) trials. Requires a neck incision and access to the carotid bifurcation.

Carotid Artery Stenting (CAS): Endovascular approach via femoral artery access. A stent is deployed across the stenosis to scaffold the artery open. Distal embolic protection devices (filter or flow-reversal) reduce the risk of procedural stroke from plaque embolization.

Both procedures aim to prevent future stroke by resolving the stenotic lesion. The choice between them depends on stenosis degree, symptom status, patient age, anatomical factors, and comorbidities.

Use the NASCET Calculator to confirm stenosis classification. The intervention decision follows that classification.

CREST Trial: The Direct Comparison

The Carotid Revascularization Endarterectomy versus Stenting Trial (CREST, 2010) was a multicenter randomized trial of 2,502 patients comparing CEA vs CAS in both symptomatic and asymptomatic patients with significant carotid stenosis.

Primary Endpoint (Composite: Stroke, MI, Death within 30 days + Ipsilateral Stroke at 4 years)

	CEA	CAS	p-value
All patients	6.8%	7.2%	0.51 (no significant difference)
Symptomatic	7.8%	8.0%	NS
Asymptomatic	4.5%	6.4%	NS

Overall conclusion: No significant difference in the primary composite endpoint between CEA and CAS.

But the Complication Profiles Differ

The “no difference” hides an important clinical distinction in which complications each procedure causes:

Complication	CEA	CAS	Clinical significance
Perioperative stroke	Lower (3.2% symptomatic)	Higher (6.0% symptomatic)	Stroke is more functionally devastating
Perioperative MI	Higher	Lower	Most MIs were small, non-Q-wave
Cranial nerve injury	~5% (mostly temporary)	Near 0%	Usually resolves; rarely permanent
Access site complications	Lower	Higher	Hematoma, pseudoaneurysm

The critical asymmetry: Strokes cause more lasting disability than most peri-procedural MIs. Patients who had strokes in CREST were significantly more functionally impaired at follow-up than those who had MIs. This asymmetry favors CEA when stroke risk is the dominant concern.

Age: The Most Important Selection Factor

CREST subgroup analysis found a crossover point at approximately age 70:

Age group	Preferred procedure	Rationale
< 70 years	CAS may be preferred or equivalent	Lower anatomical risk for CAS; CEA cranial nerve injury slightly more impactful in younger working-age patients
≥ 70 years	CEA preferred	Higher CAS stroke risk with age (tortuous vessels, calcification, increased embolic load); CEA benefit clearly exceeds CAS in older patients

Why age affects CAS risk: Older patients have more complex aortic arch anatomy, more calcified and tortuous carotid vessels, and greater atherosclerotic burden — all of which increase the technical difficulty of CAS and the risk of embolic events from wire and catheter manipulation.

Most current guidelines recommend CEA as first choice for patients ≥70 years with symptomatic stenosis ≥70%.

Symptomatic vs Asymptomatic: Different Evidence

Symptomatic Patients (≥50% NASCET)

CREST showed CAS had a significantly higher stroke risk than CEA in symptomatic patients specifically (CAS 6.0% vs CEA 3.2% stroke rate). This difference was not seen in asymptomatic patients.

Recommendation for symptomatic ≥70%: CEA is preferred, especially for patients ≥70 years. CAS is acceptable for symptomatic patients who are high surgical risk (see below).

Asymptomatic Patients (≥60% NASCET)

For asymptomatic patients, CREST showed no significant difference between CEA and CAS in any subgroup. The overall trend slightly favored CAS in younger asymptomatic patients, but this was not statistically significant.

The larger question for asymptomatic patients is whether any revascularization is better than optimized medical therapy alone — this is addressed separately in Asymptomatic Carotid Stenosis Management.

Patient Selection: Who Gets CAS vs CEA

Prefer CAS when:

High surgical risk: Contralateral ICA occlusion, previous CEA on the same side, previous neck radiation, high carotid bifurcation, hostile neck (prior surgery, tracheostomy)
Significant cardiac risk: Recent MI (< 6 weeks), unstable angina, severe COPD, severe aortic stenosis — general anesthesia risk is high
Age < 70 with otherwise equivalent anatomy
Patient preference after full informed discussion

Prefer CEA when:

Age ≥ 70
Symptomatic stenosis (lower procedural stroke risk than CAS)
Anatomically favorable: Normal aortic arch, non-tortuous access vessels
Contralateral stenosis/occlusion (CEA under regional anesthesia allows neurological monitoring)
Standard surgical risk with no specific contraindications

Either approach appropriate when:

Age < 70, symptomatic, medically fit
Asymptomatic patients meeting treatment criteria
Institutional expertise strongly favors one approach

Long-Term Outcomes: 10 Years Post-CREST

10-year follow-up of CREST (published 2016) showed:

No significant difference in ipsilateral stroke over 10 years between CEA and CAS
The early procedural period (30 days) continues to be the main differentiator
Beyond the perioperative period, durability of both procedures is equivalent

In-stent restenosis: CAS carries a risk of in-stent restenosis requiring re-intervention. Post-CAS surveillance with duplex ultrasound is standard (see Carotid Duplex Ultrasound Velocity Criteria for post-stent velocity thresholds).

Clinical note: Procedure selection requires multidisciplinary team assessment. These guidelines represent general evidence — individual patient anatomy, institutional expertise, and patient preference all influence the final decision.